Eli Lilly and Co at Goldman Sachs Healthcare Conference Transcript

Jun 12, 2023 / 08:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst

Okay. Let's kick off the afternoon session here. I hope everyone enjoyed the lunchtime discussion and has had a positive and productive morning so far. My name is Chris Shibutani. I'm a member of the research team.

We are thrilled to be able to present Lilly at our conference here: Anat Ashkenazi, the CFO; and also really appreciative of the entire team that's out here, the stellar IR team, Joe Fletcher, Lauren Zierke; and James Gilroy is also here, for those of you lucky enough to get into conversations, talking about market access, which is obviously extremely topical.

Questions and Answers:

Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst

So many inbound questions. Obviously, the center of gravity of our conversation is very clear. One of the things that I like to do personally, however, is that since this is a conversation as well between you and me is to make sure that we understand who you are.

We spent a little bit
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot